The deal adds to recent biotech M&A activity as well as signals pharma’s continued interest in pills for inflammatory conditions.Eli Lilly has agreed to buy Dice Therapeutics for about $2.4 billion in a deal that gives the pharmaceutical giant a promising oral autoimmune disease drug in clinical testing.Lilly will buy Dice, a young biotechnology company […]
